14. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results. 0164. This was offset by approximately $0. Jerry Silver, inventor of. 84 +2. Receives Up to $1. (the “Company” or “NervGen”) is a publicly traded. NervGen’s share price has dropped by 6. Stock After deciding where to buy NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury. NervGen's lead drug candidate, NVG-291, is currently planned for a Phase 1b/2a clinical trial. What this means: InvestorsObserver gives Nervgen Pharma Corp (NGENF) an overall rank of 32, which is below average. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Find market predictions, NGENF financials and market news. Vancouver, British Columbia--(Newsfile Corp. 1. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that it has been awarded a grant. 3915 +0. Vancouver, Canada. - June 27, 2023) - NervGen Pharma Corp. 5 per cent loss. The Company also announced that it has granted 150,000 incentive stock options to Mr. NervGen plans to initiate. 19 at the beginning of 2023. Vancouver, Canada. View real-time NGENF stock price and news, along with industry-best analysis. 8 million as of September 30, 2023, compared to $22. 00 per share. - September 5, 2023) - NervGen Pharma Corp. July 14, 2022 at 9:05 AM · 10 min read. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. Browse analyst ratings and price targets on all stocks. 1. View daily, weekly or monthly format back to when NervGen Pharma Corp. Currency in CAD Follow 1. About NervGen. 108% on the last trading day (Friday, 17th Nov 2023), rising from $1. is a clinical-stage biotech company. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. This was offset by approximately $2. NervGen Pharma Corp. 09. All options. Receives Up to $1. Vancouver, British Columbia--(Newsfile Corp. NervGen's lead drug candidate, NVG-291, is currently planned for a Phase 1b/2a clinical. Since then, NGENF stock has increased by 19. NOT FOR DISTRIBUTION TO U. View real-time stock prices and stock quotes for a full financial overview. Vancouver - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received Institutional Review Board (IRB) approval for its landmark Phase 1b/2a proof-of-concept clinical trial protocol of its proprietary lead compound, NVG. +1. News Ideas Financials Technicals Forecast . 19 at the beginning of 2023. 1m. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp. Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017, under the Business Corporations Act (British Columbia). , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience’s Neuroscience. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or. Market Average Movement. AZO. NervGen Pharma Corp () Stock Market info Recommendations: Buy or sell NervGen Pharma stock? Toronto Stock Market & Finance report, prediction for the future: You'll find the NervGen Pharma share forecasts, stock quote and buy / sell signals below. NERVGEN PHARMA CORP. NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. Menu. 42. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board. 0 million as of March 31, 2023. 02:06:08 2021-04-01 pm EDT 5-day change 1st Jan Change. 14: CI Nervgen Pharma Corp. Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with. Nervgen Pharma Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. NervGen Pharma is registered under the ticker OTCQB:NGENF . 07. 30(-0. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that the U. Latest Financial Results Quarter Ended September 30, 2023 Financial Statements MD&A Past Financial Results 2023 Quarter Ended June 30, 2023 Financial Statements MD&A Quarter Ended March 31, 2023 Financial Statements MD&A 2022 Year Ended December 31, 2022 Quarter Ended September 30, 2022 Quarter Ended June 30,. Bill Radvak is a co-founder and has been the Executive Chairman or Chairman of NervGen since its inception. - May 15, 2023) - NervGen Pharma Corp. Vancouver, Canada August 2, 2022 – NervGen Pharma Corp. 0164 / +1. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo. For more information. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. The company’s lead target. Vancouver, British Columbia--(Newsfile Corp. Firm Analyst Encode Ideas, LP Hogan Mullally Paradigm Capital Scott McAuley, PhD NervGen Pharma Corp. or […] NervGen Pharma Corp. - October 25, 2022) - NervGen Pharma Corp. yahoo. (the “Company” or “NervGen”) is a publicly traded. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. For instance, just consider the fact that Wall Street analysts are now estimating peak annual sales for Biogen’s new drug will range from $10 billion to $50 billion. Opens the Market (CNW Group/TMX Group Limited) Industrial Alliance Securities analyst Chelsea Stellick has launched coverage of NervGen Pharma (NervGen Pharma Stock Quote. C. Dr. 39 to a day high of $1. 0 million as of March 31, 2021, compared to $5. Currency in CAD. NervGen Pharma press release (OTCQX:NGENF): Q3 GAAP EPS of -$0. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The stock has stayed mostly between $1 and $3 over that time period, with. 419 CAD Historical index on TSX Venture Exchange : C "Should I invest in NervGen Pharma. +3. View real-time NGEN stock price and news, along with industry-best analysis. For NervGen Pharma, we've compiled three additional factors you should further research: Risks : Be aware that NervGen Pharma is showing 5 warning signs in our investment analysis , and 3 of those. Forecast Changes; Commodities. 35%) Crude Oil 75. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Discover historical prices for NGEN. V) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The NervGen Pharma Corp. View the latest NervGen Pharma Corp. Valneva has brought its vaccine against Chikungunya fever to market maturity. A high-level overview of NervGen Pharma Corp. Radvak has been the chief executive officer and director of multiple start-up companies. CA64082X2032. NOT FOR DISTRIBUTION TO U. Loading more data. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. 6 million. Today ||| 52-Week Range. Alnylam Pharmaceuticals Inc: Kkvsytx: $20. com. S. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI),. Toronto Stock Market & Finance report, prediction for the future: You'll find the NervGen Pharma share forecasts, stock quote and buy / sell signals below. Vancouver - NervGen Pharma Corp. NervGen Pharma (NGENF) has announced the appointment of Mr. 950 CAD. 9800 +0. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. NervGen Pharma Corp. 3 Bil: BMRN Biomarin Pharmaceutical Inc: Jdmlf: $15. Nancy Thompson. was tempered with the announcement of a slow growth forecast ahead. V) stock news and headlines to help you in your trading and investing decisions. NervGen Pharma Corp. Find the latest NervGen Pharma Corp. Restoring Life's Potential by Creating Innovative Solutions for the Treatment of Nervous System Damage | NervGen is a publicly traded (TSX-V. 5 million from the exercise of stock options and common share purchase warrants. Canadian clinical-stage biotech company, NervGen Pharma has enjoyed some positive results over the last few years. (NGEN:CA) stock. The following discussion is management's assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. For more information. 19%) Crude Oil 76. 87%. Current Price 1. 2021 ANNUAL FINANCIAL STATEMENTS 5 1. After the height of the COVID-19. The Company has granted 800,000 incentive stock options exercisable at a price of $3. 1. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. - October 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system. About NervGen . 3. S. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo. NervGen Pharma Corp. 5%. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen Pharma Corp. Nervgen Pharma appoints Kelly as president, CEO. NervGen Pharma Corp. April 6, 2022 – NervGen Pharma Corp. 5 million as of December 31, 2022. (NGENF) stock price, news, historical charts, analyst ratings and financial information from WSJ. ’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury. C. (the "Company" or "NervGen") and should be read in conjunction with the accompanying consolidated financial statements and related notes thereto for the period ended September 30, 2021. 94(+4. Investor. These lofty numbers are. (TSXV:NGEN) added to S&P/TSX Venture Composite Index 2022 Vancouver - NervGen Pharma Corp. NervGen Pharma Corp. 1. Vancouver, Canada. - February 28, 2022) - NervGen Pharma Corp. NervGen Pharma Corp. View the latest NervGen Pharma Corp. NervGen Pharma press release (NGENF): Q2 GAAP EPS of -$0. NGENF | Complete NervGen Pharma Corp. EST Real Time Quote About NervGen Pharma Corp. CI. Find the latest NervGen Pharma Corp. Top Analyst Stocks. All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial results for the year ended December 31, 2022 and provided an operational update,. NervGen Pharma General Information. , (TSX-V: NGEN) (OTCQX: NGENF), is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system. **Adjusted close price adjusted for splits and dividend and/or capital gain distributions. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. (NGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to. - November 12, 2021) - NervGen Pharma Corp. C. Vancouver, Canada--(Newsfile Corp. NervGen Pharma Corp. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself. 63% 6 months 11. 22%. This was offset by approximately $0. - NervGen Pharma Corp. What does it mean to sell short NervGen Pharma stock? Short selling NGENF is an investing strategy that aims to generate trading profit from NervGen Pharma as its price is falling. 5 million as of December 31, 2022As at September 30, 2023, we have achieved three of the five milestones in the grant, and received US$1. , a (formerly publicly listed) medical device company (which continues to carry on that. 70 -3. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " the " Company "), a biotech company dedicated to creating innovative. - April 10, 2023) - NervGen Pharma Corp. July 14, 2022— NervGen Pharma Corp. (NGENF) Stock Price, Quote, News & Analysis NGENF NervGen Pharma Corp. NervGen Pharma Corp (NGENF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. stock indexes jumped more than 1% Tuesday morning, with the coming close to a 2% gain. On July 13, 2022, we closed a non-brokered private placement of 10,150,000 units of the Company at a price of US$1. This was offset by approximately $3. 1. , a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will host a 1-hour panel. stock news by MarketWatch. Ruffolo exercisable at a price of $1. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 Nov. 92 million. com - September 5 at 5:11 PM. 'NervGen made. View the best growth stocks for 2023 here . NervGen's lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " or the " Company "), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that renowned neuroscientist, Dr. Stock-based compensation 3,415,360 1,293,687 Unrealized foreign exchange 16,610 133,070 Changes in non-cash working capital: Accounts receivable 59,908 (96,659). Mr. Today ||| 52-Week Range. NervGen Pharma Corp. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative. 2021 ANNUAL FINANCIAL STATEMENTS 5 1. NervGen Pharma to Receive More Than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury. September 12, 2022 – NervGen Pharma Corp. 78 per share for a period of 10 years and vest equally every month over a three-year period. Vancouver, Canada. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the first quarter ended March 31, 2023. 87 -0. 10% most volatile stocks in CA Market. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI),. Get a free in-depth analysis of NervGen Pharma (TSE:NGEN) stock. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a. View real-time stock prices and stock quotes for a full financial overview. CI. Vancouver, British Columbia-- (Newsfile Corp. Vancouver, British Columbia-- (Newsfile Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for. 13% Year to date 10. finance. Jerry Silver, inventor of NervGen's lead drug candidate. NervGen Pharma Corp Registered Shs Reg S -144A- Accred Inv Past Events. NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. Get NervGen Pharma Corp (NGEN. NervGen Pharma Announces Leadership Transition. NGENF shares are trading down $0. Vancouver, British Columbia--(Newsfile Corp. Kelly currently serves on the Board of Directors of ARS Pharmaceuticals, which he joined in May 2019. The stock has stayed mostly between $1 and $3 over that time period, with. For the upcoming trading day on Monday, 20th we expect NervGen Pharma Corp. All options. Read more. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 2022: CI NervGen Pharma Corp. announced the appointment of Mr. *Close price adjusted for splits. . A measure of how much a stock or commodity has risen or fallen over a one-year period. Stock After deciding where to buy NervGen Pharma Corp. CI. 3%. NervGen Pharma Corp. com. March 8, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce the appointment of Daniel Mikol, MD, PhD, as the. (TSX-V: NGEN;. Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. During the last trading day the stock fluctuated 2. The company’s. 3564. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291. 11%) At close: 02:05PM EST 1d 5d 1m 6m YTD 1y 5y Max NervGen Pharma's stock was trading at $1. - May 15, 2023) - NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. July 22, 2020 — NervGen Pharma Corp. February 14, 2023 […] Cash and Investments: NervGen had cash and investments of $14. (the "Company" or "NervGen") and should be read in conjunction with the accompanying consolidated financial statements and related notes thereto for the period ended June 30, 2022. +1. Complete NervGen Pharma Corp. 8 million as of September 30, compared to $22. . NGENF | Complete NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing. 2. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. 97 NGEN 0. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date. - May 4, 2021) - NervGen Pharma Corp. NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. 0015 (+0. , (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer’s disease clinical trial at the 2022 Alzheimer’s. Find the latest NervGen Pharma Corp. U. NervGen Pharma Corp. NervGen Pharma Corp. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017, under the Business Corporations Act (British Columbia). The company’s lead target. Vancouver, British Columbia-- (Newsfile Corp. Vancouver, British Columbia--(Newsfile Corp. As of Nov 01. Wall Street Stock Market & Finance report, prediction for the future: You'll find the NervGen Pharma share forecasts, stock quote and buy / sell signals below. With a revolutionary drug that could reverse the damage caused by Alzheimer’s disease, the company is certainly growing and has some ambitious plans. C. Cash and investments of $18. Share your ideas and get valuable. Nature of business . NervGen Pharma Corp. 5 million as of December 31, 2022. Vancouver, Canada. - July 14, 2022) - NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022. 5 million as of December 31, 2022. Feb. (NGEN. NGEN PB Ratio vs Fair Ratio. NervGen Pharma Stock Forecast, NGEN stock price prediction. NervGen Pharma Corp. 36. 50 per unit, for aggregate gross proceeds of. Top Smart Score Stocks. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. Forecast Changes; Commodities. 88%. +1. - September 11, 2023) - NervGen Pharma Corp. operates as a regenerative medicine. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. to open at $1. 5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve InjuryNervGen Pharma (NGENF) will release its next earnings report on Nov 15, 2023. NervGen Pharma Corp. Vancouver, British Columbia-- (Newsfile Corp. - August 22, 2023) - NervGen Pharma Corp. 34,947. Cash and investments of $18. Vancouver, British Columbia--(Newsfile Corp. 21%) At close: 03:58PM EST. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results. NervGen Pharma Corp. 1 million in proceeds from the exercise of options and. Daniel Mikol, will present at the 2023 International Spinal. V) TSXV - TSXV Real Time Price. 89%. — NervGen Pharma Corp. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen Pharma Corp. - February 14, 2023) - NervGen Pharma Corp. Stock-based compensation 4,015,673 3,415,360 Unrealized foreign exchange (31,377) 16,610 Changes in non-cash working capital: Accounts receivable (1,408) 59,908. Vancouver, British. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. (TSXV:NGEN) added to S&P/TSX Venture Composite Index 2022Vancouver - NervGen Pharma Corp. Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repair Lukashev brings over 20 years’ experience including work at Biogen and the ALS Therapy Development Institute Vancouver, Canada. | 1,176 followers on LinkedIn. - April 10, 2023) - NervGen Pharma Corp. - November 8, 2023) - NervGen Pharma Corp. NervGen Pharma Corp. well as stock -based compensation expense for which there was no comparable expense in the same period in the previousNervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine. 6 million as of June 30, 2022, compared to $12. The stock could jump quickly if the Company receives EU. Vancouver, Canada. News + Insights.